{"entity":{"type":"insider","cik":"0001324617","url":"/insider/0001324617","json_url":"/insider/0001324617.json","name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":7,"first":"2009-06-10","last":"2014-10-29","span_basis":"filed_date"},"name_variants":[{"name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","source":"filing","n_filings":7,"first_seen":"2009-06-10","last_seen":"2014-10-29"}],"transactions":[{"id":6692498,"accession":"0001104659-14-074955","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-14-074955","line_url":"/filing/0001104659-14-074955#line-3","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"PROTEON THERAPEUTICS INC","issuer_ticker":"PRTO","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Freund John Gordon; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56038.0,"shares_display":"56,038","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":560380.0,"total_display":"560,380.00","total_whole":"560,380","shares_owned_after":1432930.0,"shares_owned_after_display":"1,432,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-27","filed_date":"2014-10-29","scope":"insider"},{"id":6692496,"accession":"0001104659-14-074955","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-14-074955","line_url":"/filing/0001104659-14-074955#line-2","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"PROTEON THERAPEUTICS INC","issuer_ticker":"PRTO","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Freund John Gordon; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-27","filed_date":"2014-10-29","scope":"insider"},{"id":6926954,"accession":"0001104659-14-012353","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-14-012353","line_url":"/filing/0001104659-14-012353#line-4","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"Skyline Venture Management IV, LLC; Skyline Venture Partners Qualified Purchaser Fund IV L P; KANEKO YASUNORI","owner_display_name":"Skyline Venture Management IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":2100000.0,"total_display":"2,100,000.00","total_whole":"2,100,000","shares_owned_after":1208920.0,"shares_owned_after_display":"1,208,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-20","filed_date":"2014-02-21","scope":"insider"},{"id":4238552,"accession":"0001181431-13-019221","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-13-019221","line_url":"/filing/0001181431-13-019221#line-5","is_derivative":false,"issuer_cik":"0001277503","issuer_name":"TETRAPHASE PHARMACEUTICALS INC","issuer_ticker":"TTPH","issuer_name_source":null,"issuer_url":"/issuer/0001277503","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; Skyline Venture Management IV, LLC","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":681012.0,"shares_display":"681,012","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":4767084.0,"total_display":"4,767,084.00","total_whole":"4,767,084","shares_owned_after":2190145.0,"shares_owned_after_display":"2,190,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-25","filed_date":"2013-03-27","scope":"insider"},{"id":3000548,"accession":"0001104659-12-041088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-12-041088","line_url":"/filing/0001104659-12-041088#line-1","is_derivative":false,"issuer_cik":"0001190418","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001190418","owner_cik":null,"owner_name":"Freund John Gordon; KANEKO YASUNORI; HOFFMAN STEPHEN J; Skyline Venture Partners Qualified Purchaser Fund IV L P; Skyline Venture Management IV, LLC","owner_display_name":"Freund John Gordon","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":284698.0,"shares_display":"284,698","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":967973.2,"total_display":"967,973.20","total_whole":"967,973","shares_owned_after":4161933.0,"shares_owned_after_display":"4,161,933","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-29","filed_date":"2012-05-31","scope":"insider"},{"id":9069653,"accession":"0001181431-11-011591","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-11-011591","line_url":"/filing/0001181431-11-011591#line-6","is_derivative":false,"issuer_cik":"0001190418","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001190418","owner_cik":null,"owner_name":"KANEKO YASUNORI; Skyline Venture Partners Qualified Purchaser Fund IV L P; HOFFMAN STEPHEN J; Skyline Venture Management IV, LLC; Freund John Gordon","owner_display_name":"KANEKO YASUNORI","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1235943.0,"shares_display":"1,235,943","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":6179715.0,"total_display":"6,179,715.00","total_whole":"6,179,715","shares_owned_after":3877235.0,"shares_owned_after_display":"3,877,235","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-18","scope":"insider"},{"id":5708229,"accession":"0001123292-09-000618","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001123292-09-000618","line_url":"/filing/0001123292-09-000618#line-3","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6100.0,"shares_display":"6,100","price_per_share":3.9046,"price_display":"3.90","price_state":"stated","total_value":23818.06,"total_display":"23,818.06","total_whole":"23,818","shares_owned_after":335400.0,"shares_owned_after_display":"335,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-15","filed_date":"2009-06-15","scope":"insider"},{"id":5708228,"accession":"0001123292-09-000618","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001123292-09-000618","line_url":"/filing/0001123292-09-000618#line-2","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3800.0,"shares_display":"3,800","price_per_share":3.9447,"price_display":"3.94","price_state":"stated","total_value":14989.86,"total_display":"14,989.86","total_whole":"14,990","shares_owned_after":341500.0,"shares_owned_after_display":"341,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-12","filed_date":"2009-06-15","scope":"insider"},{"id":5708227,"accession":"0001123292-09-000618","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001123292-09-000618","line_url":"/filing/0001123292-09-000618#line-1","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40700.0,"shares_display":"40,700","price_per_share":3.8447,"price_display":"3.84","price_state":"stated","total_value":156479.29,"total_display":"156,479.29","total_whole":"156,479","shares_owned_after":345300.0,"shares_owned_after_display":"345,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-11","filed_date":"2009-06-15","scope":"insider"},{"id":5662500,"accession":"0001123292-09-000578","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001123292-09-000578","line_url":"/filing/0001123292-09-000578#line-3","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36000.0,"shares_display":"36,000","price_per_share":3.9569,"price_display":"3.96","price_state":"stated","total_value":142448.4,"total_display":"142,448.40","total_whole":"142,448","shares_owned_after":386000.0,"shares_owned_after_display":"386,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-10","filed_date":"2009-06-10","scope":"insider"},{"id":5662499,"accession":"0001123292-09-000578","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001123292-09-000578","line_url":"/filing/0001123292-09-000578#line-2","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47500.0,"shares_display":"47,500","price_per_share":3.9872,"price_display":"3.99","price_state":"stated","total_value":189392.0,"total_display":"189,392.00","total_whole":"189,392","shares_owned_after":422000.0,"shares_owned_after_display":"422,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-09","filed_date":"2009-06-10","scope":"insider"},{"id":5662498,"accession":"0001123292-09-000578","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001123292-09-000578","line_url":"/filing/0001123292-09-000578#line-1","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"ARCA biopharma, Inc.","issuer_ticker":"ABIO","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":"0001324617","owner_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_display_name":"Skyline Venture Partners Qualified Purchaser Fund IV L P","owner_url":"/insider/0001324617","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65708.0,"shares_display":"65,708","price_per_share":4.2063,"price_display":"4.21","price_state":"stated","total_value":276387.5604,"total_display":"276,387.56","total_whole":"276,388","shares_owned_after":469500.0,"shares_owned_after_display":"469,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-06-08","filed_date":"2009-06-10","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001359931","name":"PROTEON THERAPEUTICS INC","url":"/issuer/0001359931","role":"Ten percent owner","n_filings":1,"first_seen":"2014-10-29","last_seen":"2014-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Ten percent owner","n_filings":1,"first_seen":"2014-02-21","last_seen":"2014-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001373707","name":"TETRAPHASE PHARMACEUTICALS INC","url":"/issuer/0001373707","role":"Ten percent owner","n_filings":1,"first_seen":"2013-03-27","last_seen":"2013-03-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2011-02-18","last_seen":"2012-05-31"},{"type":"issuer","type_label":"ISSUER","cik":"0000907654","name":"ARCA biopharma, Inc.","url":"/issuer/0000907654","role":"Other","n_filings":2,"first_seen":"2009-06-10","last_seen":"2009-06-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001324617","retrieved_at":"2026-08-24T14:10:52+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}